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PCV32
SOCIOECONOMIC RELEVANCE OF TREATMENT OF
CHRONIC HEART FAILURE STAGE NYHA II WITH
CRATAEGUS EXTRACT WS® 1442—A PROSPECTIVE 3-YEAR
PHARMACOECONOMIC STUDY
Rychlik R1, Pfeil T1, Daniel D1, Habs M2, Klapper HG2
1Institute of Empirical Health Economics, Burscheid, Germany; 2Dr.
Willmar Schwabe Arzneimittel, Karlsruhe, Germany
OBJECTIVES: A prospective 3-year observational study has
been conducted from 1999 to 2002 to evaluate the pharma-
coeconomics of hawthorn-extract treatment of CHF at stage
NYHA II. In a cost-utility-analysis (CUA) hawthorn treatment
(crataegus extract WS® 1442 as mono- or add-on-therapy) was
compared to any other treatment option. Interim results of the
study were presented in 2001 and 2002, now the ﬁnal results 
are available. METHODS: Open, non-randomized observa-
tional cohort study with matched-pairs evaluation. The ﬁrst
cohort (Hawthorn-Cohort, HC) comprised patients receiving
hawthorn-extract therapy of CHF; in the second cohort 
(Conventional-Cohort, CC) patients with any other treatment
were observed. A number of 116 pairs were necessary for eval-
uation. For measuring HRQL the EuroQoL-5D was used.
Matching criteria were demographic factors and clinical diag-
nosis. The perspective of the German statutory health insurance
funds was applied. RESULTS: From 140 study centres 614
patients ﬁnished the study (HC: 383; CC: 231). Thereof 153
pairs could be established. Mean direct costs per year for HC
and CC amounted to 807€ (median: 511€) and 798€ (median:
525€), respectively (p = 0.905). Cost-driving factor was drug
acquisition (median HC: 287€, CC: 280€; p = 0.521). Signiﬁ-
cantly fewer prescriptions were done in HC for concomitant
ACE-inhibitors, diuretics, digitalis, and beta-blockers. The clin-
ical symptoms dyspnea and fatigue in HC were signiﬁcantly
improved in comparison to CC. During 3 years in the HC 0.240
QALYs were gained (CC: 0.234; p = 0.867). Costs per QALY
gained amounted to 10,113€ and 10,244€ for HC and CC,
respectively. CONCLUSIONS: Hawthorn extract WS® 1442
represents an effective treatment alternative in early stages of
CHF. Outcomes and costs are comparable to treatment with
ACE-inhibitors, diuretics, digitalis, and/or beta-blockers, which
are recommended by international guidelines. The symptoms
dyspnea and fatigue, which markedly affect the patients’ daily
activities, can be improved with WS® 1442.
PCV33
MODELING THE ECONOMIC IMPACT OF NEW IMPLANTABLE
DEFIBRILLATORS WITH A LONGER LIFETIME
Lamarsalle L1,Vainchtock A2, Le Heuzey JY3, Matalon C4, Hazard JR4
1GYD institut—division of IMS Health, Lyon, France; 2GYD institut—
division of IMS Health; 3Hôpital Européen Georges Pompidou;
4Guidant France SAS
OBJECTIVES: Vitality 2EL, a new implantable deﬁbrillator
(ICD), presents a major advantage: a longer lifetime increasing
delay before replacement leading to less reimplantations. This
study aims to compare direct medical costs, using this new ICD,
Vitality 2EL, versus its main competitors in France. METHODS:
The ﬁrst step was to identify among patients included into
EVADEF (French national registry of ICD-implanted patients), 
7 homogeneous groups according to age at ﬁrst implant. 
Then, within each group, we determined average ages and life
expectancies using Deale’s method and data from the French
national statistical institute (INSEE). A Markov model was built
using DATA Tree age Pro 2004 taking into account complica-
tion rates from literature. Direct medical costs were assessed
from the French health care payer’s perspective and a 2.5% dis-
count rate was applied. This model was applied to those 7
groups, per single & dual chamber deﬁbrillators (VR & DR), in
primary and secondary prevention, and for warranted period
(deﬁned by manufacturers) and projected longevity at 15%/50%
pacing. RESULTS: The model shows an average cost savings
range from 34 to 6356€ per patient with Vitality 2EL versus
competitors. CONCLUSION: Implanting a longer lifetime ICD
is clinically beneﬁcial for patients. Furthermore, we demon-
strated that it allows cost savings for health care payers.
PCV34
COST-EFFECTIVENESS OF ANTICOAGULATION WITH
BIVALIRUDIN VS. HEPARIN AND GLYCOPROTEIN INHIBITORS
IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY
INTERVENTION IN SWEDEN
Borg S1, Persson U1, Conradson TB2, Ericsson K2
1Swedish Institute for Health Economics, Lund, Sweden; 2Nycomed
Group, DK-4000 Roskilde, Denmark
OBJECTIVE: To analyse the cost-effectiveness of anticoagula-
tion with bivalirudin compared to heparin and GlycoProtein
Inhibitors IIb/IIIa (GPIs) in patients undergoing Percutaneous
Coronary Intervention (PCI) in Sweden. METHODS: As treat-
ment practice varies between hospitals, e.g. the fraction of
patients receiving GPI varies, the model analyses a patient cohort
where heparin is combined with GPIs to a variable percentage
(% GPIs) and the remaining patients receive heparin monother-
apy. The Swedish Council on Technology Assessment in Health
Care has estimated that GPIs are being used in a range of
40–50% of all PCIs. Abciximab is the only GPI with indication
for PCI in Sweden, and it was therefore used as the comparator.
Pooled data from applicable studies (REPLACE-2, EPISTENT,
ESPRIT), provided probabilities for the events; death, myocar-
dial infarction (MI), urgent revascularisation (UR) and major
and minor bleedings according to the TIMI deﬁnitions. Treat-
ment costs (year 2004) were collected for each complication
from four Swedish hospitals, and ofﬁcial drug prices from the
Swedish pharmacopeia. The model was evaluated using sto-
chastic evaluation, in a Swedish Health Care perspective, in a
30-day time frame. The modelled patient population was on
average 63 years of age, 75% male. RESULTS: Compared to a
40–50% usage of GPIs, treatment with bivalirudin reduced (p <
0.05) all complications (e.g. by 9.3 MIs, 1.9 URs, 14.4 bleedings
and 1.5 deaths in 1000 treated patients, of which 40% received
a GPI), and at the same time signiﬁcantly reduced total costs for
drugs and health care (87 SEK/patient, 95% CI 21 to 157 at
40% GPIs, or 935 SEK/patient, 95% CI 867 to 997 at 50%
GPIs). CONCLUSIONS: Treatment with bivalirudin as com-
pared to heparin and GPIs, signiﬁcantly reduced all studied com-
plications, and resulted in signiﬁcant savings in total costs of
drugs and health care in Sweden.
PCV35
ECONOMIC ASSESSMENT OF SWITCHING TO EZETIMIBE 
CO-ADMINISTERED WITH SIMVASTATIN IN SPAIN FOR A
COHORT OF PATIENTS NOT AT GOAL ON ATORVASTATIN
MONOTHERAPY
Davies GM1,Alemao E2, Nocea G3,Yin D2, Cook JR1
1Merck & Co., Inc, Blue Bell, PA, USA; 2Merck & Co, Whitehouse
Station, NJ, USA; 3Merck, Sharp & Dohme de España, Madrid, Spain
OBJECTIVE: Assess cost-effectiveness of switching patients to
ezetimibe 10mg (EZ10) co-administration with simvastatin 
20mg (S20) versus an atorvastatin titration strategy (patients are
titrated to goal or maximum atorvastatin dose of 80mg) in CHD
and CHD equivalent patients not at goal with atorvastatin 
10mg (A10) monotherapy. Method: Decision-analytic model
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developed to project lifetime costs and beneﬁts of lipid therapy.
Clinical trial data were used to estimate LDL-C reductions for
different treatment strategies. Effect of LDL-C reductions on
CHD event rates was estimated using Framingham equations
and Spanish Instituto Nacional de Estadística data on nonCHD-
related mortality. Direct costs of CHD events in Spain, Spanish
prices for simvastatin, atorvastatin and EZ10 were used to
project lifetime costs. Model was run for a population consist-
ing of all CHD and CHD-equivalent patients started on A10 in
an observational Lipid Lowering Treatment study conducted in
Spain, and not at LDL-C goal after 60 days of treatment.
RESULTS: For these patients N = 54 (mean age 62.5 years,
64.8% male, lipid proﬁle on A10 mean LDL-C 148.7mg/dl, 
TC 225.9mg/dl, HDL 45.9mg/dl), switching to EZ10 co-
administered with S20 compared to atorvastatin titration is pro-
jected to increase the life expectancy from 15.99 to 16.31 years
for CHD patients and from 18.11 to 18.23 years for CHD equiv-
alent patients with a discounted incremental cost per life year
gained of 7,855 EURO for CHD patients and 15,356 for CHD
equivalent patients. CONCLUSION: Switching to EZ10 co-
administered with simvastatin for CHD and CHD equivalent
patients not at goal on atorvastatin is projected to be a cost-
effective alternative to atorvastatin titration.
PCV36
ECONOMIC EVALUATION OF PRIMARY PREVENTION OF CVD
EVENTS WITH STATINS IN ITALY
Bustacchini S1, Ruffo P1, Mantovani LG2
1Pﬁzer Italia srl, Rome, Italy; 2University of Milan, Milan, Italy
OBJECTIVES: Cardiovascular diseases (CVD) are the leading
cause of morbidity and mortality. Treatment with statins has
shown to be effective in controlling cholesterol levels in dyslipi-
demic subjects and in preventing CVD. The objective of this
analysis was the evaluation of the economic impact of the CVD
primary prevention with statins in Italy. METHODS: Alterna-
tives: market mix for statins (low dosages assumed as initial
dosages) marketed in Italy (weighted with the current market
shares) compared with no intervention. Population: sample of
high-risk subjects with an absolute CV risk level ≥ 2% per year,
derived from a population study conducted in the Verona area
in Italy. Perspective: National Health Service (NHS). Technique:
cost-effectiveness analysis, making economic and health projec-
tions in a hypothetical cohort of 1000 subjects in primary pre-
vention; an incremental cost per life year gained (ICER LYG) has
been calculated. Time: 10 years. Costs: drugs and direct medical
costs quantiﬁed in using NHS tariffs expressed in Euro 2003.
Effects: the effects of different statins in controlling cholesterol
levels, as measured with the CURVES study (Jones P et al, 1998)
has been used to model coronary (CHD) morbidity and mortal-
ity from CVD with the Framingham risk equations (Anderson
KM et al, 1990). RESULTS: A primary CVD preventive inter-
vention with statins in a hypothetical cohort of 1000 high-risk
subjects can avoid 70 CHD events and 28 CVD deaths, thus 
projecting 138 LYG. After having considered costs for drugs
(4,789,542€) and savings due to events avoided (319,722€), the
net cost of the intervention is 4,469,820€ with a ICER LYG of
32,458€. CONCLUSIONS: The cost-effectiveness proﬁle of
CVD primary preventive intervention with statins is in the range
of what is considered cost-effective in absolute values by the 
scientiﬁc community.
PCV37
ECONOMIC EVALUATION OF TRANSESOPHAGEAL
ECHOCARDIOGRAPHY (TEE) GUIDED CARDIOVERSION IN
THE ANTICOAGULATION IN CARDIOVERSION USING
ENOXAPARIN (ACE) TRIAL FROM THE PERSPECTIVE OF
STATUTORY HEALTH INSURANCE (SHI) IN GERMANY
Schädlich PK1, Lehmacher W2, Huppertz E3, Grewe R3, Brecht JG1
1InForMed GmbH—Outcomes Research and Health Economics,
Ingolstadt, Bavaria, Germany; 2Institute for Medical Statistics,
Informatics, and Epidemiology of the University of Cologne, Cologne,
NRW, Germany; 3Aventis Pharma Deutschland GmbH, Bad Soden
am Taunus, Hesse, Germany
OBJECTIVES: To estimate—from the German SHI perspec-
tive—economic consequences of using the low-molecular-weight
heparin enoxaparin subcutaneously (ENOX) instead of intra-
venous unfractionated heparin followed by oral phenprocoumon
(UFH/PPC) for anticoagulation in patients undergoing TEE-
guided early electrocardioversion from nonvalvular atrial ﬁbril-
lation (AF). METHODS: As ENOX is noninferior to UFH/PPC
in preventing deaths and ischemic, embolic, and hemorrhagic
events [Stellbrink C, et al. ACE trial. Circulation 2004], a cost-
minimization analysis (CMA) was performed. The target 
variable “incremental cost for ENOX versus UFH/PPC” was
quantiﬁed using a modelling approach based on decision-tree
technique. The CMA encompassed 28 (26–30) treatment days
with phase I of 5 (3–8) days comprising diagnostics, initiation of
anticoagulation, and cardioversion. Phase II with the remaining
days comprised continued anticoagulation. Resource use was
veriﬁed by a survey in the in- and outpatient sectors. Costs 
were given by SHI expenses and were quantiﬁed by multiplying
utilised resource items by the price or tariff of each item, accord-
ing to German Health Care regulations. RESULTS: In the base-
case analysis, phase I was outpatient based for the majority of
ENOX patients opposed to inpatient treatment for all UFH/PPC
patients, whereas phase II was entirely outpatient based for both
patient groups. There were savings of 579€ per patient with
ENOX (892€) compared to UFH/PPC (1471€). Comprehensive
sensitivity analyses (impact analysis, Monte Carlo simulation)
showed the robustness of the model. Expenses for the inpatient-
based phase I with UFH/PPC had by far the greatest inﬂuence
on the extent of savings obtained. Simultaneous random varia-
tion of all model parameters within their empirically given inter-
vals revealed savings obtained by ENOX in 93% of 10,000
simulated comparisons versus UFH/PPC. CONCLUSIONS: In
TEE-guided early electrocardioversion of nonvalvular AF, anti-
coagulation with ENOX offers SHI in Germany an enormous
saving potential when used instead of UFH/PPC.
PCV38
COSTS OF MYOCARDIAL INFARCTION TREATMENT IN
RUSSIAN FEDERATION
Avxentieva M,Vorobjov PA, Sura M
Moscow Medical Academy, Moscow, Russia
OBJECTIVE: To calculate costs for patients with myocardial
infarction (MI) in common medical practice in Russian Federa-
tion. METHODS: Data on resource use for hospital treatment
of patients with acute myocardial infarction were extracted from
99 medical charts at 3 hospitals at Moscow, Tula and Vladimir.
Data on resource use for out-patient follow-up for patients after
acute myocardial infarction were identiﬁed according to experts’
opinion. A total of 12 experts ﬁlled in the questionnaire for iden-
tifying typical follow-up strategy for 1.5 years after MI. Direct
medical costs were calculated on the basis of price-lists for
medical services and median prices for drugs given in a whole-
sale pharmaceutical informational bulletin. RESULTS: Median
